Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,793
  • Shares Outstanding, K 48,980
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,610 K
  • EBIT $ -32 M
  • EBITDA $ -31 M
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.82
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.82
  • Most Recent Earnings $-0.19 on 11/13/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 280.19% (-130.78%)
  • Historical Volatility 89.24%
  • IV Percentile 49%
  • IV Rank 16.69%
  • IV High 1,204.24% on 12/02/25
  • IV Low 95.04% on 12/10/24
  • Expected Move (DTE 14) 0.0510 (5.70%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 36
  • Volume Avg (30-Day) 84
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 4,447
  • Open Int (30-Day) 6,802
  • Expected Range 0.8431 to 0.9451

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 2
  • High Estimate -0.15
  • Low Estimate -0.20
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7030 +27.18%
on 12/01/25
1.1901 -24.87%
on 11/11/25
+0.0056 (+0.63%)
since 11/04/25
3-Month
0.7030 +27.18%
on 12/01/25
1.2605 -29.07%
on 09/11/25
-0.3259 (-26.71%)
since 09/04/25
52-Week
0.7030 +27.18%
on 12/01/25
2.2818 -60.82%
on 12/09/24
-1.2559 (-58.41%)
since 12/04/24

Most Recent Stories

More News
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.8941 (+5.05%)
PDS Biotechnology: Q3 Earnings Snapshot

PDS Biotechnology: Q3 Earnings Snapshot

PDSB : 0.8941 (+5.05%)
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval...

PDSB : 0.8941 (+5.05%)
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.8941 (+5.05%)
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy  PDS01ADC reprograms natural killer (NK) cells to possess characteristics...

PDSB : 0.8941 (+5.05%)
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.8941 (+5.05%)
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Three abstracts accepted for presentation, including one rapid oral abstract session Presentations to highlight ongoing clinical and translational research across PDS Biotechnology’s immunotherapy...

PDSB : 0.8941 (+5.05%)
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most dominant type of head and neck cancer in the US by mid 2030s...

PDSB : 0.8941 (+5.05%)
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Radiopharm Theranostics Limited Sponsored ADR (RADX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PDS Biotechnology (PDSB – Research Report) and Radiopharm Theranostics Limited Sponsored ADR (RADX –...

RADX : 4.59 (+2.34%)
PDSB : 0.8941 (+5.05%)
PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda ® (pembrolizumab) alone (10.8 months) and Keytruda ® + chemotherapy (12.3 months) in...

PDSB : 0.8941 (+5.05%)

Business Summary

PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary...

See More

Key Turning Points

3rd Resistance Point 1.0079
2nd Resistance Point 0.9720
1st Resistance Point 0.9330
Last Price 0.8941
1st Support Level 0.8581
2nd Support Level 0.8222
3rd Support Level 0.7832

See More

52-Week High 2.2818
Fibonacci 61.8% 1.6787
Fibonacci 50% 1.4924
Fibonacci 38.2% 1.3061
Last Price 0.8941
52-Week Low 0.7030

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar